Medizinische Universität Graz - Research portal
Selected Publication:
Bodner, K; Bodner-Adler, B; Obermair, A; Windbichler, G; Petru, E; Mayerhofer, S; Czerwenka, K; Leodolter, S; Kainz, C; Mayerhofer, K.
Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.
Gynecol Oncol. 2001; 81(2):160-165
Doi: 10.1006/gyno.2001.6152
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESS) in relation to their clinical and pathologic features and to identify possible prognostic factors. METHODS: Thirty-one patients with histologically proven ESS were included in the analysis. Endometrial stromal sarcoma is characterized by proliferations composed of cells with endometrial stromal cell differentiation. A breakpoint of 10 mitoses per 10 high-power fields was used in the statistical analysis to distinguish between low-grade and high-grade endometrial stromal sarcoma and to evaluate the prognostic value of mitotic count in patients with ESS. RESULTS: The median follow-up time was 72 months (range 34-110). The median overall survival of the 31 patients was 127 months, resulting in a 5-year overall survival rate of 62%. Adjuvant therapy was administered to 25 patients; among those, 20 patients received postoperative radiotherapy and 5 patients received chemotherapy. Ten of the irradiated patients and 3 patients undergoing chemotherapy developed disease recurrence. Concerning the response rate to adjuvant chemotherapy, 1 patient showed a complete response, 1 patient a partial response, 1 patient stable disease, and 2 patients progressive disease. Altogether, 14 patients developed recurrent disease with a median disease-free survival of 11 months (range 5-60). Twelve patients died of the disease. A univariate model revealed that early tumor stage (P < 0.0007), low myometrial invasion (P < 0.008), and low mitotic count (P < 0.005) were associated with a lengthened overall survival in patients with endometrial stromal sarcoma. Age and adjuvant therapy did not influence overall survival of patients with ESS. CONCLUSION: Early tumor stage, low myometrial invasion, and low mitotic count are associated with a lengthened overall survival in patients with ESS.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Analysis of Variance -
- Chemotherapy, Adjuvant -
- Endometrial Neoplasms - pathology
- Female - pathology
- Follow-Up Studies - pathology
- Humans - pathology
- Hysterectomy - pathology
- Middle Aged - pathology
- Neoplasm Recurrence, Local - pathology
- Ovariectomy - pathology
- Prognosis - pathology
- Radiotherapy, Adjuvant - pathology
- Retrospective Studies - pathology
- Salpingostomy - pathology
- Sarcoma, Endometrial Stromal - pathology
- Survival Analysis - pathology
- Find related publications in this database (Keywords)
- endometrial stromal sarcoma
- prognostic parameters
- tumor stage
- mitotic count
- myometrial invasion